iECURE CEO Joe Truitt and founder Jim Wilson

Jim Wil­son biotech iECURE gets fresh $65M to push pe­di­atric liv­er dis­ease gene ther­a­py in­to the clin­ic

Jim Wil­son-found­ed biotech iECURE has wrapped a $65M Se­ries A ex­ten­sion round to get its lead can­di­date — a gene re­place­ment ther­a­py for a rare in­her­it­ed liv­er dis­ease known as or­nithine tran­scar­bamy­lase de­fi­cien­cy, or OTC — in­to the clin­ic.

This round was co-led by No­vo Hold­ings and LYFE Cap­i­tal, fol­lowed by ini­tial in­vestors Ver­sant and Or­biMed as well. In Sep­tem­ber 2021, iECURE raised a $50 mil­lion Se­ries A led by the lat­ter two. The new cash in­fu­sion will get iECURE through an ini­tial in-hu­man tri­al, which CEO Joe Tru­itt told End­points News iECURE hopes to read out in 2024.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.